SBE 13 HCl 10mg | Purity Not Available
Selleck Chemicals
SBE 13 HCl is a potent and selective PLK1 inhibitor with IC50 of 200 pM, >4000-fold selectivity over Aurora A kinase, Plk2 and Plk3.
More Information Supplier PageSBE 13 HCl is a potent and selective PLK1 inhibitor with IC50 of 200 pM, >4000-fold selectivity over Aurora A kinase, Plk2 and Plk3.
More Information Supplier PageCCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
More Information Supplier PageCCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
More Information Supplier PageBMH-21 is a DNA intercalator, which binds ribosomal DNA and inhibits RNA polymerase I (Pol I) transcription.
More Information Supplier PageYK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).
More Information Supplier PageYK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).
More Information Supplier PageSP2509 (HCI-2509) is a selective histone demethylase LSD1 inhibitor with IC50 of 13 nM, showing no activity against MAO-A, MAO-B, lactate dehydrogenase and glucose oxidase. SP2509 induces apoptosis and promotes autophagy.
More Information Supplier PageSP2509 (HCI-2509) is a selective histone demethylase LSD1 inhibitor with IC50 of 13 nM, showing no activity against MAO-A, MAO-B, lactate dehydrogenase and glucose oxidase. SP2509 induces apoptosis and promotes autophagy.
More Information Supplier PageOF-1 is a potent inhibitor of BRPF1B and BRPF2 bromodomain with Kd of 100 nM and 500 nM, respectively.
More Information Supplier PageSalirasib (Farnesylthiosalicylic acid, FTS) is a potent competitive prenylated protein methyltransferase (PPMTase) inhibitor with Ki of 2.6 μM, which inhibits Ras methylation. Salirasib exerts antitumor effects and induces autophagy. Phase 2.
More Information Supplier Page